9 results about "Intraarticular Injections" patented technology

The present disclosure provides methods and compositions comprising hyaluronic acid (HA) hydrogel in combination with a saturated fatty acid for treating osteoarthritis. In some embodiments, aspects of the disclosure relate to pharmaceutical compositions comprising HA hydrogel in combination with a steroid. In some embodiments, the pharmaceutical compositions may be administrable via local, topical, and injection. In some embodiments, the pharmaceutical composition may be administrable by intra-articular injection.

The present invention relates to a composition for intra-articular use for the treatment of osteoarthritis (OA), comprising cross-linked hyaluronic acid or a salt or derivative thereof, clodronic acid or an equivalent salt thereof, and acetate buffer.

The application belongs to the technical field of medical decision support, and discloses a knee joint postoperative distal deep vein thrombosis prediction system; by acquiring multi-dimensional parameters such as coagulation function, metabolic function, inflammation ratio index and intra-articular injection history, the sodium hyaluronate injection history is converted into an articular lesion severity score, an inflammation-coagulation coupling characteristic vector and a metabolic disturbance correction model are innovatively constructed, and the synergistic effect among multiple systems is captured. A penalty regression model with cross-validation is used for sparse prediction factor screening, redundant variables are screened out through a regularization path shrinkage technology, and key prediction factors are reserved. Finally, an individualized thrombosis risk probability nomogram is constructed, and the prediction accuracy is verified through resampling calibration. The application realizes the multi-system integration of inflammation, coagulation, metabolism and joint degeneration factors, converts the complex statistical model into a clinically friendly tool, and optimizes the postoperative thrombosis prevention and control strategy.

This document presents a novel composition and method for treating osteoarthritis using a cannabinoid-based nanoplatform administered via intra-articular injection. The composition includes phytocannabinoids such as CBG and CBC, along with hyaluronic acid, type II collagen, and calcium gluconate, embedded within a nanoplatform designed to enhance bioavailability and ensure controlled release in the synovial space. Tailored for osteoarthritis patients, the treatment alleviates joint pain, stiffness, reduced mobility, inflammation, sensations of friction, muscle weakness, and joint deformity. Cannabinoids act through multiple mechanisms, including interaction with CB1 and CB2 receptors, cytokine modulation, inhibition of NF-κB, and activation of the TRPV1 receptor, providing a potent anti-inflammatory effect. The formulation aims to halt cartilage degeneration, reduce pain, and slow osteoarthritis progression. The production process uses nanoemulsification techniques to create particles smaller than 200 nm, with pre-sterilization through membrane filtration, ensuring both efficacy and safety.

The present disclosure relates to an ultrasound guided intraarticular administration of a combination of a composition comprising pooled mesenchymal stromal cells, and mid molecular weight hyaluronic acid for treatment of osteoarthritis. The disclosure also provides methods for increasing levels of anti-inflammatory marker and decreasing levels of disease progression marker in a human subject suffering from osteoarthritis through the use of the said combination. The present disclosure accordingly also relates to a kit comprising the said composition and the hyaluronic acid as such for the said use and treatment.

This invention relates to alginate–pectin polymer-based quercetin microspheres as an anti-inflammatory drug delivery system for intra-articular application in osteoarthritis. The microspheres were prepared using an ionic gelation method through an ionotropic aerosolization technique, in which a solution of quercetin and alginate–pectin polymer with a total concentration of approximately 3% was sprayed into a calcium chloride (CaCl₂) solution using a pressure of approximately 40 psi and a spray distance of approximately 8 cm. The alginate–pectin ratios used included 1:1 and 1:2, with the addition of lyophilisate in the form of lactose or maltodextrin during the lyophilization process. The results showed that increasing the pectin fraction and the use of maltodextrin increased drug loading and entrapment efficiency of quercetin, while a 1:1 ratio produced microspheres with a more compact structure and higher yield.The present invention provides a formulation and method for producing quercetin microspheres with adjustable properties, thus potentially being used as a controlled-release intra-articular injectable preparation for the therapy of joint inflammation.

This invention discloses the application of sulfadimidine in the preparation of drugs for treating osteoarthritis. This invention is the first to demonstrate the significant efficacy of intra-articular injection of sulfadimidine in the treatment of osteoarthritis (OA); the results show that sulfadimidine can not only significantly relieve the symptoms of osteoarthritis but also improve the metabolic function of chondrocytes, thereby slowing the progression of arthritis. Traditional treatment methods mainly include intra-articular injection of anesthetic drugs, joint lubricants (such as sodium hyaluronate), glucocorticoids, and platelet-rich plasma (PRP). However, these methods each have limitations, such as significant short-term effects but potential long-term side effects. Sulfamidine, as a novel treatment method, not only has good efficacy but also fewer side effects, providing a new approach to the drug treatment of osteoarthritis.

The present invention relates to a pharmaceutical composition suitable for intra-articular injection, comprising an anesthetic and an immediate-release or controlled-release dosage form containing colchicine. Furthermore, the present invention relates to a pharmaceutical composition in powder form comprising an anesthetic and an immediate-release or controlled-release dosage form containing colchicine, wherein the controlled-release dosage form containing colchicine is in the form of fine particles. Furthermore, the present invention relates to a pharmaceutical composition in powder form comprising an anesthetic and an immediate-release or controlled-release dosage form containing colchicine, wherein the controlled-release dosage form containing colchicine is in the form of fine particles, a kit, and the use of the pharmaceutical composition or kit in the treatment of crystal-associated acute inflammatory arthritis and amorphous acute inflammatory arthritis, particularly crystal-associated arthropathy or erythema or acute type tendinitis and capsulitis, by intra-articular injection of the pharmaceutical composition into the joint, providing immediate and overall treatment-long analgesia.

The present disclosure provides methods and compositions comprising hyaluronic acid (HA) hydrogel in combination with a saturated fatty acid for treating osteoarthritis. In some embodiments, aspects of the disclosure relate to pharmaceutical compositions comprising HA hydrogel in combination with a steroid. In some embodiments, the pharmaceutical compositions may be administrable via local, topical, and injection. In some embodiments, the pharmaceutical composition may be administrable by intra-articular injection.